ALCAR.PA Stock Bounces at €0.099 on EURONEXT May 1

ALCAR.PA stock is trading at €0.099 on EURONEXT today, showing signs of an oversold bounce after severe long-term declines. Carmat SA, a French medical device company specializing in total artificial hearts, has experienced a brutal 93% drop over the past year. The stock’s current price represents a potential reversal point for investors watching this healthcare innovator. With 807,348 shares traded and a market cap of €6.36 million, ALCAR.PA stock remains highly volatile. Today’s intraday session offers a critical moment to assess whether this bounce signals genuine recovery or temporary relief.

ALCAR.PA Stock Price Action and Technical Setup

ALCAR.PA stock opened at €0.0994 and is trading within a tight range between €0.097 and €0.11 today. The stock has collapsed from its 52-week high of €1.51 to its current level, representing a staggering decline. Volume today stands at 807,348 shares, slightly above the average of 797,166, suggesting modest interest in this oversold bounce.

The technical picture shows ALCAR.PA stock trading near its 52-week low of €0.085, which provides a potential support floor. The 50-day moving average sits at €0.14751, while the 200-day average is €0.59472, both well above current prices. This wide gap between moving averages indicates extreme weakness, yet oversold conditions often precede sharp bounces in distressed stocks.

Carmat SA Fundamentals and Financial Health

Carmat SA operates in the medical devices sector within healthcare, developing artificial heart solutions for end-stage heart failure patients. The company, headquartered in Vélizy-Villacoublay, France, employs 1,620 people and was founded in 2008. Despite its innovative mission, ALCAR.PA stock reflects severe financial stress across multiple metrics.

The company shows negative earnings per share of -€1.15 and a price-to-earnings ratio of -0.086, indicating ongoing losses. Revenue per share stands at just €0.307, while net income per share is -€2.256. Free cash flow per share is negative at -€1.967, showing the company burns cash to fund operations. These metrics explain why ALCAR.PA stock has suffered such dramatic declines, though they also suggest the worst may be priced in for an oversold bounce scenario.

Market Sentiment and Trading Activity

Trading Activity: ALCAR.PA stock shows relative volume of 1.01x average, indicating slightly elevated interest despite the stock’s distressed state. The intraday session has produced flat price action with zero change today, suggesting consolidation after months of selling pressure. Liquidation pressure appears to have eased, as the stock holds above its 52-week low.

Liquidation: The company’s debt-to-market cap ratio of 9.09x reveals significant leverage relative to market value, a red flag for equity holders. However, the current ratio of 1.70x suggests adequate short-term liquidity to meet obligations. Working capital of €13.28 million provides a buffer, though negative tangible asset value of -€51.2 million indicates the balance sheet is severely impaired. Track ALCAR.PA on Meyka for real-time updates on this oversold bounce.

Meyka AI Rating and Investment Perspective

Meyka AI rates ALCAR.PA with a grade of B based on a total score of 69.27. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests a HOLD recommendation, reflecting the stock’s mixed fundamental picture.

The company’s three-year revenue growth per share of 1.14% shows minimal expansion, while five-year growth reaches 275.6%, indicating historical volatility. Operating cash flow remains deeply negative at -€1.90 per share, and the company has not paid dividends. These grades are not guaranteed and we are not financial advisors. For oversold bounce traders, ALCAR.PA stock presents a speculative opportunity based on technical extremes rather than fundamental strength.

Final Thoughts

ALCAR.PA stock trades at €0.099 on EURONEXT, presenting an oversold bounce opportunity for tactical traders willing to accept extreme risk. Carmat SA’s artificial heart technology addresses a genuine medical need, yet the company’s negative cash flows and impaired balance sheet explain the 93% annual decline. The stock’s proximity to 52-week lows and elevated relative volume suggest potential short-term relief, though fundamental recovery remains uncertain. Investors should recognize this as a speculative play on technical extremes, not a fundamental turnaround. Monitor earnings announcements and cash burn rates closely before committing capital to this distressed healthcare stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.